Mylan Receives FDA Approval for Metolazone TabletsPITTSBURGH--(BUSINESS WIRE)--Dec. 24, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Metolazone Tablets USP, 2.5 mg. Metolazone is the generic version of Celltech Pharmaceuticals, Inc. Zaroxolyn^®.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc. that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.